WALTHAM, Mass., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a leading innovator and provider of
high-value products to improve the process of manufacturing biologic drugs, today announced that Tony J. Hunt, Chief Executive
Officer, will present at Baird’s annual Global Healthcare Conference being held September 7-8, 2016 in New York. The Repligen
presentation will take place at 8:30 a.m. on Thursday, September 8th.
A live webcast of the presentation will be accessible through the Investor Events section of the Company’s website, and will be available for replay for a limited
period of time following the conference event.
About Repligen Corporation
Repligen Corporation (NASDAQ:RGEN) is a bioprocessing company focused on the development, manufacture and commercialization of
highly innovative products used to manufacture biologic drugs. Our bioprocessing products are sold to major life sciences
companies, biopharmaceutical development companies and contract manufacturing organizations worldwide. We are the leading
manufacturer of Protein A affinity ligands, a critical component of Protein A resins that are used to separate and purify
monoclonal antibody-based therapeutics. In upstream processes, our XCell™ ATF systems and cell culture growth factors are used to
accelerate and increase product yield during the fermentation stage of biologic drug manufacturing. In downstream processes, we
market our innovative line of OPUS® chromatography columns that we deliver pre-packed with our customers’ choice of resin for their
bench-scale through clinical production-scale purification needs. Repligen’s corporate headquarters are in Waltham, MA (USA) and
our manufacturing facilities are located in Waltham, MA, Lund, Sweden and Weingarten, Germany.
This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are
cautioned that statements in this press release which are not strictly historical statements including, without limitation,
statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar expressions,
constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that
could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings
with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements,
except as required by law.
Contact: Sondra S. Newman Senior Director Investor Relations Repligen Corporation (781) 419-1881 snewman@repligen.com
